Lunglife Ai Regulatory News (LLAI)

LungLife AI, Inc. (the "Company" or "LungLife")

 Data Supporting LungLB to be Presented at the Association for Molecular Pathology

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to announce that our two abstract submissions to the Association for Molecular Pathology1 (AMP) have been accepted for both presentation at their flagship 2024 Annual Meeting & Expo in Vancouver, BC, Canada from November 19-23rd, and also for publication in the November 2024 issue of The Journal of Molecular Diagnostics.

The acceptance of our abstracts for both presentation and publication is a recognition of the interest in, and significant potential of, our LungLB® test. They provide us with an exciting opportunity to further raise market awareness and understanding of the LungLB® test as we highlight the results of two important LungLB® studies demonstrating the analytic and clinical validity of the test to a broad range of clinical laboratories, healthcare providers, and industry representatives.

In addition, the data presented serve to expand the clinical evidence for the LungLB® test which is important to encourage and support adoption of the test by centres.

Commenting on the acceptance, Paul Pagano, Chief Executive Officer of LungLife, said: 

"We are excited to have these two abstracts accepted for both presentation and publication by the AMP and believe this marks another important step in the pathway to commercialisation.

AMP brings together a diverse community of physicians, scientists, and laboratory professionals from academic and community medical centres, government, and industry. We are looking forward to furthering discussions that allow us to demonstrate our commitment to advancing early detection of lung cancer and making a significant impact in this critical area of healthcare."

Full details of the abstracts are as follows:

Abstract Title: Analytical Validation of the LungLB test: a blood-based 4-color FISH assay for the evaluation of indeterminate pulmonary nodulesPresenter: Eric Vail, MD, Cedars-Sinai Medical Center

Abstract # 1874291

Abstract Title: Clinical Validation of LungLB: a Circulating Genetically Abnormal Cell-based Classifier for Indeterminate Lung Nodule EvaluationPresenter: Paul Pagano, PhD

Abstract # 1874647

For further information please contact:

Notes

1. Originally founded in 1995, AMP advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care, and is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation, and develop practice guidelines on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.